Physician profile
Kofi Del Quist
NPI 1295933349
$17,827.67
in general payments reported to CMS, 2019-2025
68 companies · $2,934 in 2025
The $2,934 reported for 2025 was more than what 82% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,733 · 2020: $503 · 2021: $1,465 · 2022: $3,740 · 2023: $3,280 · 2024: $3,172 · 2025: $2,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,274 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,274.17 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,460.51 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $2,094.84 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,640.03 | 2019-2025 | |
| Abbvie INC. | $1,308.29 | 2021-2025 | |
| Biogen, INC. | $809.41 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $703.58 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $628.67 | 2021-2025 | Ajovy, Austedo Xr |
| Pfizer INC. | $565.62 | 2023-2025 | |
| Neurelis, INC. | $565.37 | 2023-2025 | Valtoco |
| Amgen INC. | $511.74 | 2019-2024 | Aimovig |
| Catalyst Pharmaceuticals, INC. | $496.17 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $476.76 | 2021-2025 | |
| Greenwich Biosciences, INC. | $357.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $349.74 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $305.56 | 2019-2022 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kofi Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.